175 related articles for article (PubMed ID: 36717670)
21. In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2.
du Manoir S; Delpech H; Orsetti B; Jacot W; Pirot N; Noel J; Colombo PE; Sardet C; Theillet C
J Pathol; 2022 Jul; 257(3):367-378. PubMed ID: 35302657
[TBL] [Abstract][Full Text] [Related]
22. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
23. 1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function.
Ma H; Qin Q; Mi J; Feng Q
BMC Pharmacol Toxicol; 2020 Sep; 21(1):67. PubMed ID: 32912307
[TBL] [Abstract][Full Text] [Related]
24. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
Ma J; Liu L; Ling Y; Zheng J
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
[TBL] [Abstract][Full Text] [Related]
25. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
27. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH
Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622
[TBL] [Abstract][Full Text] [Related]
29. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
30. Suppression of the Antioxidant System and PI3K/Akt/mTOR Signaling Pathway in Cisplatin-Resistant Cancer Cells by Quercetin.
Hasan AAS; Kalinina EV; Tatarskiy VV; Volodina YL; Petrova АS; Novichkova MD; Zhdanov DD; Shtil AA
Bull Exp Biol Med; 2022 Oct; 173(6):760-764. PubMed ID: 36322312
[TBL] [Abstract][Full Text] [Related]
31. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
32. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
[TBL] [Abstract][Full Text] [Related]
33. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
[TBL] [Abstract][Full Text] [Related]
34. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.
Yin F; Liu L; Liu X; Li G; Zheng L; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2014 Jul; 32(1):362-72. PubMed ID: 24842157
[TBL] [Abstract][Full Text] [Related]
36. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
37. GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p.
Li Y; Zhai Y; Chen Y
J Ovarian Res; 2021 Aug; 14(1):108. PubMed ID: 34425872
[TBL] [Abstract][Full Text] [Related]
38. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
39. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
40. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
